Operating
Alnylam Pharmaceuticals·Cash Flow Statement·15 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net income | -$16.9M | -$111.6M | -$83.8M | -$18.3M | -$66.3M | $251.1M | $111.5M | $206M |
| Change in accounts payable | $74.5M | $83.6M | — | -$157.7M | $184.1M | $223.5M | — | -$176M |
| Change in accounts receivable | -$9.6M | $37.1M | $59.5M | $7.4M | $136.9M | $399.9M | — | $110.4M |
| Net cash from operating activities | $124.2M | $43.7M | -$94.7M | -$120.3M | $155.7M | $325.1M | $163.6M | $70.5M |
| Stock-based compensation | $89.3M | $45.8M | $91.6M | $56.7M | $111.7M | $108.2M | $71.6M | $70.2M |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | $29.5M | $30.7M | $35.3M | $54.6M | $16.8M | $40.9M | — | $66.2M |
| Depreciation and amortization | $15M | $14M | $14.2M | $14.4M | $13.9M | $13.8M | $13.5M | $13.6M |
| Change in other assets | -$61.7M | $8.3M | -$25.3M | $32.8M | $0 | $20.7M | $71M | $6.3M |
| Increase (Decrease) in Prepaid Expense and Other Assets | -$61.7M | $8.3M | -$25.3M | $32.8M | $0 | $20.7M | $71M | $6.3M |
| Change in inventories | -$6.8M | -$5.9M | -$849K | -$6.2M | -$11.1M | -$5M | — | $3.3M |
| Other working capital changes | -$11.8M | -$13.9M | -$6.8M | -$19.4M | -$18.5M | — | — | $3M |
| Change in deferred revenue | -$190.9M | -$3.1M | -$12.8M | -$27.3M | -$13.1M | -$12.5M | $0 | -$1.6M |
| Net gains (losses) on investments | -$1.4M | -$1.6M | -$166K | -$956K | -$1.4M | — | — | $0 |
| Equity Securities, FV-NI, Gain (Loss) | -$1.4M | -$1.6M | -$166K | -$956K | -$1.4M | — | — | $0 |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | $31.8M | $31.8M | $31.8M | $59.6M | $59.6M | $59.6M | $59.6M | — |